CR/iStock via Getty Images
With the recent approval in China of Innovent Biologics’ (OTCPK:IVBIY) mazdutide as the first-ever dual GLP-1/glucagon receptor (GCP) for obesity, observers are already making comparisons of the drug to Novo Nordisk’s (NVO) Wegovy (semaglutide) and Eli Lilly’s (
